ClinicalTrials.gg
Active, not recruitingNCT06554054Updated Aug 14, 2024

A Study of GZR18 Tablet in Chinese Healthy Subjects

A Phase 1 interventional study of GZR18 in Diabetes Mellitus, Type 2, sponsored by Gan and Lee Pharmaceuticals, USA. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.
  • Registered 4 months after the study started (first participant enrolled Apr 2024, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 — 2 open to participants now, 5 under way, 1 of them phase 3. bofanglutide · Diabetes Mellitus, Type 2.

Enrollment
5th of 10
92 · median 91
Started
2024
with 1 other
Phase 1
4 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
6 of 10
Gan and Lee Pharmaceuticals, USA

Among the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 2 that started in 2024, is one of 4 in phase 1, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of the trial is to investigate the the bioavailability, pharmacokinetics, pharmacodynamics, safety and tolerance of single and multiple doses of GZR18 tablet in healthy subjects.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects sign voluntarily.
  2. Age 18-55 at screening (both included),male or female(male only for part A).
  3. At screening, 20.0 kg/m2 ≤ ≤ 24.9 kg/m2, body weight≥54.0 kg.
  4. Female subjects were HCG negative at screening and baseline

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating at screening.
  2. History of drug abuse within 1 year prior to screening, with a positive drug abuse screening result at screening or before dosing.
  3. Abnormal fasting blood glucose at screening, or impaired glucose tolerance, or history of hypoglycemia within 3 months prior to screening.
  4. History of the following diseases with a definite diagnosis within 6 months prior to screening: cardiovascular disease, hematologic disease, respiratory disease, abnormal liver function due to acute and chronic hepatitis or other reasons, abnormal renal function, endocrine and metabolic system disease, neuropsychiatric disease, skin and subcutaneous tissue disease, musculoskeletal system disease, immune system disease, or the presence of other diseases that may interfere with the interpretation of study results.
  5. Those who have any food allergies or special dietary requirements and cannot follow a uniform diet.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Experimental: Part A (single dose)

    Drug: GZR18 tablet Three single-dose cohorts of GZR18 tablet administered according to an ascending dose design. Progression to next dose will be based on safety evaluation. Sequential cohorts. Active Comparator: GZR18 injection Single-dose administered s.c. (under the skin).

    Drug: GZR18

  • Experimental
    Experimental: Part B (multiple dose)

    Drug:GZR18 tablet GZR18 tablet administered as two multiple dose cohorts, to test the different meal time effect. Parallel assignment

    Drug: GZR18

Interventions

  • DrugGZR18

    Oral administered the GZR18 tablet

06

What researchers measure

Primary outcomes

  1. AE and SAE

    Incidence of Adverse Events and Severe Adverse Events

    Time frame: 22 days and 35 days

  2. Relative bioavailability of GZR18 tablet

    Fr =AUC0-t(GZR18 tablets)/AUC0-t(GZR18 injection)×100%

    Time frame: 22 days and 35 days

  3. ADA and NAb

    Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab)

    Time frame: 22 days and 35 days

Secondary outcomes

  1. Cmax

    Maximum plasma drug concentration

    Time frame: 22 days and 35 days

  2. AUC0-t

    Area under the curve from 0 through the time of the last accurately measurable concentration

    Time frame: 22 days and 35 days

  3. AUC0-24h

    Area under the curve from 0 h to 24 hours

    Time frame: 22 days and 35 days

07

Study locations

1 site
  • Study Site 01
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2024, 8 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 8 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 14, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Dec 9, 2024
CompletionEst.
Dec 9, 2024
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06554054
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Apr 1, 2024
Primary completion
Dec 9, 2024 (estimated)
Completion
Dec 9, 2024 (estimated)
Last update
Aug 14, 2024

Study contacts

Xiao Min, Ph.D
study director · Gan & Lee Pharmaceuticals Co., Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion